Specialty chemicals M&A in the first five months of 2026 has not been about big new combinations. It has been about large incumbents emptying their portfolios, mid-cap operators picking up adjacent niches, and one of the year’s most-watched cross-border deals getting smaller rather than larger as it approaches closing. The volume headlines describe a rebound; the deal mix says corporate refocus.

A Kearney report published on 4 March 2026 found that global chemicals deal value rose roughly 18 percent year over year in 2025, but the lift came from a handful of large, strategically driven transactions rather than a broad return of buyer confidence. The pipeline of announced and pending divestitures from BASF, BP, Occidental, DuPont and Corteva, combined with stabilising valuations, was expected to keep activity selective into 2026. The deals printed since January have largely confirmed that read.

BASF Coatings is the largest open file

The single largest specialty chemicals transaction still working through closing in mid-2026 is BASF’s sale of its Coatings business to Carlyle. The deal, announced in October 2025, values the unit at an enterprise value of EUR 7.7 billion. BASF will receive pre-tax cash proceeds of roughly EUR 5.8 billion at closing and will retain a 40 percent stake in the standalone company, while Carlyle takes majority control. BASF expects the transaction to close in the second quarter of 2026, subject to remaining regulatory approvals.

BASF Coatings confirmed on 25 March 2026 that Jens Luehring will be appointed Chief Executive Officer upon closing, signalling that the operational stand-up of the new entity is being prepared in parallel with the regulatory process. The coatings carve-out is the single most consequential strand of the broader BASF “Winning Ways” portfolio reshape, both in scale and in the structural change it imposes on the group’s automotive OEM and refinish customer relationships.

The same restructuring is also moving the BASF Agricultural Solutions business into a legally independent subsidiary. The hive-down was notarised on 10 and 18 March 2026 and approved by the subsidiary’s shareholders’ meeting on 21 April 2026, with the BASF AGM endorsing the broader transaction in late April. The target is a partial Frankfurt IPO in 2027; for 2026 the activity is structural rather than transactional, which is itself characteristic of the carve-out-heavy mix this year.

For context on what BASF’s portfolio reshape means for the chemicals capex cycle and the process-analytics vendors that sell into it, see our Q1 chemicals capex review.

Honeywell-Johnson Matthey: a megadeal gets smaller

The second open file is Honeywell’s purchase of Johnson Matthey’s Catalyst Technologies business. The original deal, announced in May 2025, valued the unit at GBP 1.8 billion. On 23 February 2026 the parties announced an amended agreement that reduces the cash consideration to GBP 1.325 billion and extends the long-stop date to 21 July 2026, with a conditional extension available to 21 August 2026. Honeywell now expects the transaction to close by the end of August 2026, subject to remaining regulatory approvals.

Johnson Matthey’s own transaction update characterised the revised price as the consequence of extended regulatory review and adjusted trading expectations for the unit during the prolonged closing period. Honeywell, for its part, continues to describe the acquisition as strategically central to Honeywell UOP’s refining, petrochemicals and renewable fuels offering, and expects it to be accretive to adjusted earnings per share in the first full year of ownership.

The amendment is a useful marker for how regulators and buyers are treating cross-border industrial transactions in this cycle. Headline values are negotiable; long-stop dates are extending; and buyers are willing to accept smaller, slower deals rather than walk. It is the opposite of the 2021-2022 environment where bidders stretched on price and timing to close.

Bolt-ons: where the volume actually is

Below the megadeal layer, the more representative 2026 transactions have been bolt-ons that sharpen a specialty franchise. Element Solutions closed its acquisition of EFC Gases & Advanced Materials on 2 January 2026 for a purchase price of approximately USD 369 million, net of cash, with a potential earn-out of up to USD 30 million in cash or 1.16 million company shares tied to EFC’s 2026 performance. The valuation, at roughly 12 times forecast 2026 adjusted EBITDA, reflects the strategic premium attached to high-purity specialty gases used in semiconductor manufacturing and aerospace. EFC is expected to contribute about USD 30 million of adjusted EBITDA in 2026 at margins above 30 percent.

BASF itself has been on both sides of bolt-on activity. On 4 March 2026 BASF and Oxidium Technologies LLC closed the sale of BASF’s Aseptrol chlorine-dioxide biocide product line, used in water purification, disinfection and dental-line cleaning. The deal is small in headline terms but characteristic of the larger pattern: a strategic seller trimming a non-core product line into a buyer that intends to redeploy the platform across adjacent end markets.

What it changes for operators

Three implications for chemicals and analytical operators. First, the carve-out pipeline is large enough that integration, separation and stand-alone IT, quality and process-analytics work will be a real budget line for the rest of 2026 - new entities like BASF Coatings under Carlyle and the hived-down BASF Agricultural Solutions will need their own operational scaffolding. Second, regulatory closing risk is real and is now reflected in revised pricing, as the Honeywell-Johnson Matthey amendment shows. Third, the bolt-on layer remains the most reliable source of deal flow, and it is concentrated in the specialty gases, biocides, advanced materials and catalysis niches where end-market growth is visible.

The instruments and analytical equipment side of the same period has shown a similar mix - large strategic moves alongside steady bolt-ons - which we covered in the Bruker Q1 review. Through mid-May the specialty chemicals tape in 2026 looks coherent rather than exuberant: large incumbents are continuing the work of refocusing, the most-watched cross-border deal is closing smaller than it was sold, and the consistent volume is in specialist bolt-ons sized for the buyer’s current cash flow rather than its ambitions.